An Olathe-based startup hopes to partner with children’s hospitals for its brain cancer treatment. For starters, TVAX Biomedical plans to enter a late-stage clinical trial of its cancer immunotherapy treatment with Children’s Mercy.
“There’s no effective therapy for (pediatric brain cancer),” said Gary Wood, TVAX's founder and chief scientific officer. “It’s not a target for big companies because the cancers are pretty rare, compared with adult cancers.”
Wood is confident in the…
An Olathe-based startup hopes to partner with children’s hospitals for its brain cancer treatment. For starters, TVAX Biomedical plans to enter a late-stage clinical trial of its cancer immunotherapy treatment with Children’s Mercy.
“There’s no effective therapy for (pediatric brain cancer),” said Gary Wood, TVAX's founder and chief scientific officer. “It’s not a target for big companies because the cancers are pretty rare, compared with adult cancers.”
Wood is confident in the…